- American City Business Journals•15 days ago
Arbutus Biopharma Corp., a two-year-old biopharmaceutical company attempting to develop a cure for hepatitis B infections, won the latest round in its ongoing dispute over a cross licensing deal it made with a Canadian drug company. This week the Supreme Court of British Columbia granted a request by Arbutus (ABUS)— which has offices in Vancouver and Doylestown, Pennsylvania — for a pre-trial injunction preventing Acuitas from sublicensing Arbutus’ lipid nanoparticle [LNP] technology until the end of October. “We are gratified by the court’s decision to grant a pre-trial injunction against Acuitas to stop Acuitas from granting unauthorized licenses and use of our LNP technology,” said Dr. Mark J. Murray, Arbutus’ president and CEO, in a prepared statement.
- GlobeNewswire•16 days ago
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 09, 2017-- Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that the company will ...
- Forbes•17 days ago
British Columbia Supreme Court Justice Dev Dley this week granted a request from Arbutus Biopharma for a pre-trial injunction that prevents a tiny company called Acuitas from sublicensing Arbutus’ lipid nanoparticle delivery technology to Moderna until the end of October.
ABUS : Summary for Arbutus Biopharma Corporation - Yahoo Finance
Arbutus Biopharma Corporation (ABUS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||2.30 x 200|
|Ask||5.30 x 500|
|Day's Range||2.55 - 2.67|
|52 Week Range||2.35 - 5.48|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.81|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|